Clinical Trials Logo

Filter by:
NCT ID: NCT06388499 Recruiting - Clinical trials for Chronic Conditions, Multiple

A Physiotherapy-led Disease-agnostic Telerehabilitation Programme for People With Chronic Health Conditions

Start date: April 16, 2024
Phase: N/A
Study type: Interventional

This protocol outlines a planned mixed methods feasibility trial which will be conducted to examine the feasibility and acceptability of a physiotherapy-led exercise-based telerehabilitation programme for groups of people with mixed chronic health conditions.

NCT ID: NCT06397703 Recruiting - Prostate Cancer Clinical Trials

ADT and SBRT vs SBRT Alone for Unfavorable Intermediate Risk Prostate Cancer

Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

For this proposed Phase III study, unfavorable intermediate risk prostate cancer patients will be randomized to receive 6 months of Androgen Deprivation Therapy (ADT) in conjunction with stereotactic body radiation therapy/radiosurgery (SBRT) directed to the prostate versus SBRT alone. The patient population will include those with National Comprehensive Cancer Network (NCCN)-defined unfavorable intermediate risk disease. All patients will be followed every 6 months for up to 5 years from the first patient randomized and will undergo a routine 24-30 months post-SBRT prostate biopsy to assess for local tumor control.

NCT ID: NCT06402747 Recruiting - Type 2 Diabetes Clinical Trials

Clopidogrel Versus Cilostazol on Vessels

Start date: April 16, 2024
Phase: Phase 4
Study type: Interventional

Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.

NCT ID: NCT06406608 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer

Start date: April 16, 2024
Phase: N/A
Study type: Interventional

This study aims to enroll non-small cell lung cancer patients who have undergone at least two rounds of standard treatment for drug resistance/recurrence. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.

NCT ID: NCT06406660 Recruiting - Clinical trials for Small Cell Lung Cancer

Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung Cancer

Start date: April 16, 2024
Phase: N/A
Study type: Interventional

This study plans to enroll 20 patients with recurrent small cell lung cancer. Patient-derived Organoid will be established, and drug sensitivity test will be conducted to intervene in the selection of clinical treatment plans. Efficacy evaluation and prognosis analysis will also be conducted. It is hoped that this study will provide a basis for the development of personalized treatment plans.

NCT ID: NCT06422286 Recruiting - Gagging Clinical Trials

Efficacy of Low-level Laser Acupuncture and Microcurrent Electrical Stimulation on Gag Reflex on Children

Start date: April 16, 2024
Phase: N/A
Study type: Interventional

the aim of the current study is to evaluate the effectiveness of the laser acupuncture in comparison to the electroacupuncure for controlling gag reflex in children

NCT ID: NCT06453668 Recruiting - ALS Clinical Trials

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

AURORA
Start date: April 16, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.

NCT ID: NCT06462326 Recruiting - Healthy Volunteer Clinical Trials

A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

Start date: April 16, 2024
Phase: Phase 1
Study type: Interventional

This is a randomized (1:1), double-blind, double-dummy, phase I study to compare the effects of Omadacycline versus Moxifloxacin on gut microbiota and the resistomes in healthy adult volunteers.The study consists of 3 phases: Screening, double-blind treatment, and follow-up. Healthy volunteers aged 18-40 years, who meet entry criteria, are randomly assigned to a treatment group using an Interactive Voice Response System/Interactive Web Response System (IxRS) and receive the first dose of the study drug.

NCT ID: NCT06467097 Recruiting - Kidney Neoplasm Clinical Trials

Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma

SABLOR
Start date: April 16, 2024
Phase: Phase 3
Study type: Interventional

To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.

NCT ID: NCT03310502 Recruiting - Obesity Clinical Trials

Variation of Genes Controlling Carbohydrate and Lipid Metabolism

CMgene
Start date: April 17, 2002
Phase:
Study type: Observational

Aim of the study is to investigate genes regulating glucose and lipid metabolism in subjects whose glucose metabolism, lipid metabolism, blood flow, or body fat distribution has been measured using positron emission tomography (PET), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS) or computed tomography (CT) as part of their previous participation in clinical trials conducted at Turku PET Centre. By combining information from PET, MRI, CT, proteomics, metabolomics and genetics analyses we aim to find connection between genetic variation and metabolic and cardiovascular disease.